M1 精神分裂症 PET 研究
2024年3月21日 更新者:Rajiv Radhakrishnan, MD、Yale University
精神分裂症中毒蕈碱 M1 受体的可用性和认知
这项探索性研究旨在检查 SZ 患者的 M1 受体可用性,并将 M1 受体可用性与认知表现的近端和远端测量相关联,即脑电图和语言记忆中诱发的 ɣ 振荡。
此外,还将探讨海马 [11C]EMO 可用性 (BPND)、诱发的 ɣ 振荡、语言记忆和疾病严重程度测量之间的关系。
研究概览
详细说明
来自死后研究的汇聚证据提供了强有力的证据,证明精神分裂症 (SZ) 患者的一个子集存在脑毒蕈碱 M1 受体缺陷。 M1 受体是 SZ 中认知缺陷的重要目标。 然而,直到现在,还无法检查 SZ 在体内 M1 受体可用性方面的异质性。 耶鲁 PET 中心开发的新型正电子发射断层扫描 (PET) 配体 [11C]EMO 提供了一个独特的机会,可以首次检查 SZ 中体内脑毒蕈碱 M1 受体的可用性,同时阐明两者之间的关系M1 受体对 SZ 认知缺陷的影响。
研究人员将使用 [11C]EMO 和高分辨率研究断层扫描仪 (HRRT) 比较 SZ 患者和年龄、性别匹配的健康对照者的 M1 受体可用性,HRRT 是一种具有高灵敏度和高分辨率的 PET 扫描仪,可用于人脑成像。 本研究将探索以下之间的关系:海马 [11C]EMO 结合(作为海马 M1 AChR 可用性的衡量标准)、语言记忆任务期间编码相关的 γ 功率、语言记忆、性别和血清乙酰胆碱水平。 这项探索性研究将提供必要的试点数据,以进行更大规模的研究,以充分调查 SZ 在 M1 受体可用性方面的异质性。
研究类型
介入性
注册 (实际的)
18
阶段
- 阶段2
联系人和位置
本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。
学习联系方式
- 姓名:Rajiv Radhakrishnan, MD
- 电话号码:4080 203-932-5711
- 邮箱:rajiv.radhakrishnan@yale.edu
研究联系人备份
- 姓名:Deepak D'Souza, MD
- 电话号码:2594 203-932-5711
- 邮箱:deepak.dsouza@yale.edu
学习地点
-
-
Connecticut
-
New Haven、Connecticut、美国、06519
- Connecticut Mental Health Center
-
-
参与标准
研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。
资格标准
适合学习的年龄
18年 至 55年 (成人、年长者)
接受健康志愿者
是的
描述
纳入标准:
- 除 DSM-5 精神分裂症或分裂情感障碍诊断外,身心健康的 18-55 岁男性和女性
- 体内没有金属的受试者可能在 MRI 扫描期间构成风险
- 没有明显的病史,包括头部外伤和出血性疾病
排除标准:
- 有临床显着疾病病史或存在的男性和女性
- 无法戒烟 5 天的吸烟者
- 患有幽闭恐惧症、有不兼容 MRI 植入物或其他 MRI 和 PET 扫描禁忌症的人
学习计划
本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。
研究是如何设计的?
设计细节
- 主要用途:诊断
- 分配:不适用
- 介入模型:单组作业
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
---|---|
实验性的:11C-EMO - 一种用于毒蕈碱 M1 受体的新型 PET 放射性示踪剂
参加者将进行一次 [11C]EMO ≤ 20 mCi 的 PET 扫描
|
放射性示踪剂 [11C]EMO 将在每次 PET 扫描开始时使用。
其他名称:
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
---|---|---|
海马 M1 可用性
大体时间:10天
|
通过 [11C]EMO 可用性 (BPND) 衡量
|
10天
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
---|---|---|
诱发 ɣ 振荡
大体时间:10天
|
通过脑电图测量
|
10天
|
口头记忆
大体时间:10天
|
通过认知评估衡量
|
10天
|
合作者和调查者
在这里您可以找到参与这项研究的人员和组织。
调查人员
- 首席研究员:Rajiv Radhakrishnan, MD、Yale University
出版物和有用的链接
负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。
一般刊物
- Weintraub S, Dikmen SS, Heaton RK, Tulsky DS, Zelazo PD, Bauer PJ, Carlozzi NE, Slotkin J, Blitz D, Wallner-Allen K, Fox NA, Beaumont JL, Mungas D, Nowinski CJ, Richler J, Deocampo JA, Anderson JE, Manly JJ, Borosh B, Havlik R, Conway K, Edwards E, Freund L, King JW, Moy C, Witt E, Gershon RC. Cognition assessment using the NIH Toolbox. Neurology. 2013 Mar 12;80(11 Suppl 3):S54-64. doi: 10.1212/WNL.0b013e3182872ded.
- Green MF, Kern RS, Heaton RK. Longitudinal studies of cognition and functional outcome in schizophrenia: implications for MATRICS. Schizophr Res. 2004 Dec 15;72(1):41-51. doi: 10.1016/j.schres.2004.09.009.
- Mesholam-Gately RI, Giuliano AJ, Goff KP, Faraone SV, Seidman LJ. Neurocognition in first-episode schizophrenia: a meta-analytic review. Neuropsychology. 2009 May;23(3):315-36. doi: 10.1037/a0014708.
- Kay SR, Opler LA, Lindenmayer JP. The Positive and Negative Syndrome Scale (PANSS): rationale and standardisation. Br J Psychiatry Suppl. 1989 Nov;(7):59-67. No abstract available.
- Gershon RC, Cella D, Fox NA, Havlik RJ, Hendrie HC, Wagster MV. Assessment of neurological and behavioural function: the NIH Toolbox. Lancet Neurol. 2010 Feb;9(2):138-9. doi: 10.1016/S1474-4422(09)70335-7. No abstract available.
- Gershon RC, Wagster MV, Hendrie HC, Fox NA, Cook KF, Nowinski CJ. NIH toolbox for assessment of neurological and behavioral function. Neurology. 2013 Mar 12;80(11 Suppl 3):S2-6. doi: 10.1212/WNL.0b013e3182872e5f.
- Lammertsma AA, Hume SP. Simplified reference tissue model for PET receptor studies. Neuroimage. 1996 Dec;4(3 Pt 1):153-8. doi: 10.1006/nimg.1996.0066.
- Green MF, Harvey PD. Cognition in schizophrenia: Past, present, and future. Schizophr Res Cogn. 2014 Mar;1(1):e1-e9. doi: 10.1016/j.scog.2014.02.001.
- Green MF, Horan WP, Lee J. Nonsocial and social cognition in schizophrenia: current evidence and future directions. World Psychiatry. 2019 Jun;18(2):146-161. doi: 10.1002/wps.20624.
- Wu Y, Carson RE. Noise reduction in the simplified reference tissue model for neuroreceptor functional imaging. J Cereb Blood Flow Metab. 2002 Dec;22(12):1440-52. doi: 10.1097/01.WCB.0000033967.83623.34.
- Mogg AJ, Eessalu T, Johnson M, Wright R, Sanger HE, Xiao H, Crabtree MG, Smith A, Colvin EM, Schober D, Gehlert D, Jesudason C, Goldsmith PJ, Johnson MP, Felder CC, Barth VN, Broad LM. In Vitro Pharmacological Characterization and In Vivo Validation of LSN3172176 a Novel M1 Selective Muscarinic Receptor Agonist Tracer Molecule for Positron Emission Tomography. J Pharmacol Exp Ther. 2018 Jun;365(3):602-613. doi: 10.1124/jpet.117.246454. Epub 2018 Apr 11.
- Oki T, Takagi Y, Inagaki S, Taketo MM, Manabe T, Matsui M, Yamada S. Quantitative analysis of binding parameters of [3H]N-methylscopolamine in central nervous system of muscarinic acetylcholine receptor knockout mice. Brain Res Mol Brain Res. 2005 Jan 5;133(1):6-11. doi: 10.1016/j.molbrainres.2004.09.012.
- Smart K, Gallezot JD, Nabulsi N, Labaree D, Zheng MQ, Huang Y, Carson RE, Hillmer AT, Worhunsky PD. Separating dopamine D2 and D3 receptor sources of [11C]-(+)-PHNO binding potential: Independent component analysis of competitive binding. Neuroimage. 2020 Jul 1;214:116762. doi: 10.1016/j.neuroimage.2020.116762. Epub 2020 Mar 19.
- Worhunsky PD, Matuskey D, Gallezot JD, Gaiser EC, Nabulsi N, Angarita GA, Calhoun VD, Malison RT, Potenza MN, Carson RE. Regional and source-based patterns of [11C]-(+)-PHNO binding potential reveal concurrent alterations in dopamine D2 and D3 receptor availability in cocaine-use disorder. Neuroimage. 2017 Mar 1;148:343-351. doi: 10.1016/j.neuroimage.2017.01.045. Epub 2017 Jan 19.
- Carruthers SP, Van Rheenen TE, Gurvich C, Sumner PJ, Rossell SL. Characterising the structure of cognitive heterogeneity in schizophrenia spectrum disorders. A systematic review and narrative synthesis. Neurosci Biobehav Rev. 2019 Dec;107:252-278. doi: 10.1016/j.neubiorev.2019.09.006. Epub 2019 Sep 7.
- Niendam TA, Ray KL, Iosif AM, Lesh TA, Ashby SR, Patel PK, Smucny J, Ferrer E, Solomon M, Ragland JD, Carter CS. Association of Age at Onset and Longitudinal Course of Prefrontal Function in Youth With Schizophrenia. JAMA Psychiatry. 2018 Dec 1;75(12):1252-1260. doi: 10.1001/jamapsychiatry.2018.2538.
- Van Rheenen TE, Cropley V, Zalesky A, Bousman C, Wells R, Bruggemann J, Sundram S, Weinberg D, Lenroot RK, Pereira A, Shannon Weickert C, Weickert TW, Pantelis C. Widespread Volumetric Reductions in Schizophrenia and Schizoaffective Patients Displaying Compromised Cognitive Abilities. Schizophr Bull. 2018 Apr 6;44(3):560-574. doi: 10.1093/schbul/sbx109.
- Wells R, Swaminathan V, Sundram S, Weinberg D, Bruggemann J, Jacomb I, Cropley V, Lenroot R, Pereira AM, Zalesky A, Bousman C, Pantelis C, Weickert CS, Weickert TW. The impact of premorbid and current intellect in schizophrenia: cognitive, symptom, and functional outcomes. NPJ Schizophr. 2015 Nov 4;1:15043. doi: 10.1038/npjschz.2015.43. eCollection 2015.
- Scarr E, Craig JM, Cairns MJ, Seo MS, Galati JC, Beveridge NJ, Gibbons A, Juzva S, Weinrich B, Parkinson-Bates M, Carroll AP, Saffery R, Dean B. Decreased cortical muscarinic M1 receptors in schizophrenia are associated with changes in gene promoter methylation, mRNA and gene targeting microRNA. Transl Psychiatry. 2013 Feb 19;3(2):e230. doi: 10.1038/tp.2013.3.
- Scarr E, Hopper S, Vos V, Seo MS, Everall IP, Aumann TD, Chana G, Dean B. Low levels of muscarinic M1 receptor-positive neurons in cortical layers III and V in Brodmann areas 9 and 17 from individuals with schizophrenia. J Psychiatry Neurosci. 2018 Aug;43(5):338-346. doi: 10.1503/jpn.170202.
- Hopper S, Pavey GM, Gogos A, Dean B. Widespread Changes in Positive Allosteric Modulation of the Muscarinic M1 Receptor in Some Participants With Schizophrenia. Int J Neuropsychopharmacol. 2019 Oct 1;22(10):640-650. doi: 10.1093/ijnp/pyz045.
- Crook JM, Tomaskovic-Crook E, Copolov DL, Dean B. Decreased muscarinic receptor binding in subjects with schizophrenia: a study of the human hippocampal formation. Biol Psychiatry. 2000 Sep 1;48(5):381-8. doi: 10.1016/s0006-3223(00)00918-5.
- Lebois EP, Trimper JB, Hu C, Levey AI, Manns JR. Effects of Selective M1 Muscarinic Receptor Activation on Hippocampal Spatial Representations and Neuronal Oscillations. ACS Chem Neurosci. 2016 Oct 19;7(10):1393-1405. doi: 10.1021/acschemneuro.6b00160. Epub 2016 Aug 12.
- Harrison PJ. Using our brains: the findings, flaws, and future of postmortem studies of psychiatric disorders. Biol Psychiatry. 2011 Jan 15;69(2):102-3. doi: 10.1016/j.biopsych.2010.09.008. No abstract available.
- Nabulsi NB, Holden D, Zheng MQ, Bois F, Lin SF, Najafzadeh S, Gao H, Ropchan J, Lara-Jaime T, Labaree D, Shirali A, Slieker L, Jesudason C, Barth V, Navarro A, Kant N, Carson RE, Huang Y. Evaluation of 11C-LSN3172176 as a Novel PET Tracer for Imaging M1 Muscarinic Acetylcholine Receptors in Nonhuman Primates. J Nucl Med. 2019 Aug;60(8):1147-1153. doi: 10.2967/jnumed.118.222034. Epub 2019 Feb 7. Erratum In: J Nucl Med. 2019 Nov;60(11):1648.
- Barch DM, Ceaser A. Cognition in schizophrenia: core psychological and neural mechanisms. Trends Cogn Sci. 2012 Jan;16(1):27-34. doi: 10.1016/j.tics.2011.11.015. Epub 2011 Dec 12.
- Carruthers SP, Gurvich CT, Rossell SL. The muscarinic system, cognition and schizophrenia. Neurosci Biobehav Rev. 2015 Aug;55:393-402. doi: 10.1016/j.neubiorev.2015.05.011. Epub 2015 May 21.
- Marino MJ, Rouse ST, Levey AI, Potter LT, Conn PJ. Activation of the genetically defined m1 muscarinic receptor potentiates N-methyl-D-aspartate (NMDA) receptor currents in hippocampal pyramidal cells. Proc Natl Acad Sci U S A. 1998 Sep 15;95(19):11465-70. doi: 10.1073/pnas.95.19.11465.
- Levey AI, Kitt CA, Simonds WF, Price DL, Brann MR. Identification and localization of muscarinic acetylcholine receptor proteins in brain with subtype-specific antibodies. J Neurosci. 1991 Oct;11(10):3218-26. doi: 10.1523/JNEUROSCI.11-10-03218.1991.
- Anagnostaras SG, Murphy GG, Hamilton SE, Mitchell SL, Rahnama NP, Nathanson NM, Silva AJ. Selective cognitive dysfunction in acetylcholine M1 muscarinic receptor mutant mice. Nat Neurosci. 2003 Jan;6(1):51-8. doi: 10.1038/nn992.
- Gould RW, Dencker D, Grannan M, Bubser M, Zhan X, Wess J, Xiang Z, Locuson C, Lindsley CW, Conn PJ, Jones CK. Role for the M1 Muscarinic Acetylcholine Receptor in Top-Down Cognitive Processing Using a Touchscreen Visual Discrimination Task in Mice. ACS Chem Neurosci. 2015 Oct 21;6(10):1683-95. doi: 10.1021/acschemneuro.5b00123. Epub 2015 Aug 5.
- Cropley VL, Scarr E, Fornito A, Klauser P, Bousman CA, Scott R, Cairns MJ, Tooney PA, Pantelis C, Dean B. The effect of a muscarinic receptor 1 gene variant on grey matter volume in schizophrenia. Psychiatry Res. 2015 Nov 30;234(2):182-7. doi: 10.1016/j.pscychresns.2015.09.004. Epub 2015 Sep 10.
- Liao DL, Hong CJ, Chen HM, Chen YE, Lee SM, Chang CY, Chen H, Tsai SJ. Association of muscarinic m1 receptor genetic polymorphisms with psychiatric symptoms and cognitive function in schizophrenic patients. Neuropsychobiology. 2003;48(2):72-6. doi: 10.1159/000072880.
- Scarr E, Cowie TF, Kanellakis S, Sundram S, Pantelis C, Dean B. Decreased cortical muscarinic receptors define a subgroup of subjects with schizophrenia. Mol Psychiatry. 2009 Nov;14(11):1017-23. doi: 10.1038/mp.2008.28. Epub 2008 Mar 4.
- Bakker G, Vingerhoets C, Boucherie D, Caan M, Bloemen O, Eersels J, Booij J, van Amelsvoort T. Relationship between muscarinic M1 receptor binding and cognition in medication-free subjects with psychosis. Neuroimage Clin. 2018 Mar 3;18:713-719. doi: 10.1016/j.nicl.2018.02.030. eCollection 2018.
- Lavalaye J, Booij J, Linszen DH, Reneman L, van Royen EA. Higher occupancy of muscarinic receptors by olanzapine than risperidone in patients with schizophrenia. A[123I]-IDEX SPECT study. Psychopharmacology (Berl). 2001 Jun;156(1):53-7. doi: 10.1007/s002130000679.
- Raedler TJ. Comparison of the in-vivo muscarinic cholinergic receptor availability in patients treated with clozapine and olanzapine. Int J Neuropsychopharmacol. 2007 Apr;10(2):275-80. doi: 10.1017/S1461145706006584. Epub 2006 Apr 6.
- Erskine D, Taylor JP, Bakker G, Brown AJH, Tasker T, Nathan PJ. Cholinergic muscarinic M1 and M4 receptors as therapeutic targets for cognitive, behavioural, and psychological symptoms in psychiatric and neurological disorders. Drug Discov Today. 2019 Dec;24(12):2307-2314. doi: 10.1016/j.drudis.2019.08.009. Epub 2019 Sep 6.
- Nathan PJ, Watson J, Lund J, Davies CH, Peters G, Dodds CM, Swirski B, Lawrence P, Bentley GD, O'Neill BV, Robertson J, Watson S, Jones GA, Maruff P, Croft RJ, Laruelle M, Bullmore ET. The potent M1 receptor allosteric agonist GSK1034702 improves episodic memory in humans in the nicotine abstinence model of cognitive dysfunction. Int J Neuropsychopharmacol. 2013 May;16(4):721-31. doi: 10.1017/S1461145712000752. Epub 2012 Aug 29.
- Shekhar A, Potter WZ, Lightfoot J, Lienemann J, Dube S, Mallinckrodt C, Bymaster FP, McKinzie DL, Felder CC. Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia. Am J Psychiatry. 2008 Aug;165(8):1033-9. doi: 10.1176/appi.ajp.2008.06091591. Epub 2008 Jul 1.
- Han M, Newell K, Zavitsanou K, Deng C, Huang XF. Effects of antipsychotic medication on muscarinic M1 receptor mRNA expression in the rat brain. J Neurosci Res. 2008 Feb 1;86(2):457-64. doi: 10.1002/jnr.21491.
- Carson RE, Barker WC, Liow J-S, Adler S, Johnson CA. Design of a motion-compensation OSEM List-mode Algorithm for Resolution-Recovery Reconstruction of the HRRT. IEEE Nuclear Science Symposium and Medical Imaging Conference; 2003; Portland, OR; 2003. p. M16-6.
- Jin X, Mulnix T, Sandiego CM, Carson RE. Evaluation of frame-based and event-by-event motion-correction methods for awake monkey brain PET imaging. J Nucl Med. 2014 Feb;55(2):287-93. doi: 10.2967/jnumed.113.123299. Epub 2014 Jan 16.
- Horti AG, Fan H, Kuwabara H, Hilton J, Ravert HT, Holt DP, Alexander M, Kumar A, Rahmim A, Scheffel U, Wong DF, Dannals RF. 11C-JHU75528: a radiotracer for PET imaging of CB1 cannabinoid receptors. J Nucl Med. 2006 Oct;47(10):1689-96.
- Gallezot JD, Nabulsi N, Neumeister A, Planeta-Wilson B, Williams WA, Singhal T, Kim S, Maguire RP, McCarthy T, Frost JJ, Huang Y, Ding YS, Carson RE. Kinetic modeling of the serotonin 5-HT(1B) receptor radioligand [(11)C]P943 in humans. J Cereb Blood Flow Metab. 2010 Jan;30(1):196-210. doi: 10.1038/jcbfm.2009.195. Epub 2009 Sep 23.
- Tzourio-Mazoyer N, Landeau B, Papathanassiou D, Crivello F, Etard O, Delcroix N, Mazoyer B, Joliot M. Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain. Neuroimage. 2002 Jan;15(1):273-89. doi: 10.1006/nimg.2001.0978.
- Innis RB, Cunningham VJ, Delforge J, Fujita M, Gjedde A, Gunn RN, Holden J, Houle S, Huang SC, Ichise M, Iida H, Ito H, Kimura Y, Koeppe RA, Knudsen GM, Knuuti J, Lammertsma AA, Laruelle M, Logan J, Maguire RP, Mintun MA, Morris ED, Parsey R, Price JC, Slifstein M, Sossi V, Suhara T, Votaw JR, Wong DF, Carson RE. Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab. 2007 Sep;27(9):1533-9. doi: 10.1038/sj.jcbfm.9600493. Epub 2007 May 9.
- Babiloni C, Vecchio F, Mirabella G, Buttiglione M, Sebastiano F, Picardi A, Di Gennaro G, Quarato PP, Grammaldo LG, Buffo P, Esposito V, Manfredi M, Cantore G, Eusebi F. Hippocampal, amygdala, and neocortical synchronization of theta rhythms is related to an immediate recall during rey auditory verbal learning test. Hum Brain Mapp. 2009 Jul;30(7):2077-89. doi: 10.1002/hbm.20648.
- Cassetta BD, Menon M, Carrion PB, Pearce H, DeGraaf A, Leonova O, White RF, Stowe RM, Honer WG, Woodward TS, Torres IJ. Preliminary examination of the validity of the NIH toolbox cognition battery in treatment-resistant psychosis. Clin Neuropsychol. 2020 Jul;34(5):981-1003. doi: 10.1080/13854046.2019.1694072. Epub 2019 Nov 29.
- Boozalis T, Teixeira AL, Cho RY, Okusaga O. C-Reactive Protein Correlates with Negative Symptoms in Patients with Schizophrenia. Front Public Health. 2018 Jan 22;5:360. doi: 10.3389/fpubh.2017.00360. eCollection 2017.
- Deng H, Kahlon RS, Mohite S, Amin PA, Zunta-Soares G, Colpo GD, Stertz L, Fries GR, Walss-Bass C, Soares JC, Okusaga OO. Elevated Plasma S100B, Psychotic Symptoms, and Cognition in Schizophrenia. Psychiatr Q. 2018 Mar;89(1):53-60. doi: 10.1007/s11126-017-9514-y.
- Mohite S, Yang F, Amin PA, Zunta-Soares G, Colpo GD, Stertz L, Sharma AN, Fries GR, Walss-Bass C, Soares JC, Okusaga OO. Plasma soluble L-selectin in medicated patients with schizophrenia and healthy controls. PLoS One. 2017 Mar 23;12(3):e0174073. doi: 10.1371/journal.pone.0174073. eCollection 2017.
- Yohn SE, Conn PJ. Positive allosteric modulation of M1 and M4 muscarinic receptors as potential therapeutic treatments for schizophrenia. Neuropharmacology. 2018 Jul 1;136(Pt C):438-448. doi: 10.1016/j.neuropharm.2017.09.012. Epub 2017 Sep 9.
- Ranganathan M, Cortes-Briones J, Radhakrishnan R, Thurnauer H, Planeta B, Skosnik P, Gao H, Labaree D, Neumeister A, Pittman B, Surti T, Huang Y, Carson RE, D'Souza DC. Reduced Brain Cannabinoid Receptor Availability in Schizophrenia. Biol Psychiatry. 2016 Jun 15;79(12):997-1005. doi: 10.1016/j.biopsych.2015.08.021. Epub 2015 Aug 29.
- D'Souza DC, Esterlis I, Carbuto M, Krasenics M, Seibyl J, Bois F, Pittman B, Ranganathan M, Cosgrove K, Staley J. Lower ss2*-nicotinic acetylcholine receptor availability in smokers with schizophrenia. Am J Psychiatry. 2012 Mar;169(3):326-34. doi: 10.1176/appi.ajp.2011.11020189.
- Esterlis I, Ranganathan M, Bois F, Pittman B, Picciotto MR, Shearer L, Anticevic A, Carlson J, Niciu MJ, Cosgrove KP, D'Souza DC. In vivo evidence for beta2 nicotinic acetylcholine receptor subunit upregulation in smokers as compared with nonsmokers with schizophrenia. Biol Psychiatry. 2014 Sep 15;76(6):495-502. doi: 10.1016/j.biopsych.2013.11.001. Epub 2013 Nov 13.
- D'Souza DC, Perry E, MacDougall L, Ammerman Y, Cooper T, Wu YT, Braley G, Gueorguieva R, Krystal JH. The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: implications for psychosis. Neuropsychopharmacology. 2004 Aug;29(8):1558-72. doi: 10.1038/sj.npp.1300496.
- Arnedo J, Svrakic DM, Del Val C, Romero-Zaliz R, Hernandez-Cuervo H; Molecular Genetics of Schizophrenia Consortium; Fanous AH, Pato MT, Pato CN, de Erausquin GA, Cloninger CR, Zwir I. Uncovering the hidden risk architecture of the schizophrenias: confirmation in three independent genome-wide association studies. Am J Psychiatry. 2015 Feb 1;172(2):139-53. doi: 10.1176/appi.ajp.2014.14040435. Epub 2014 Oct 31. Erratum In: Am J Psychiatry. 2014 Oct;171(10):1124.
研究记录日期
这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。
研究主要日期
学习开始 (实际的)
2021年4月20日
初级完成 (实际的)
2023年10月31日
研究完成 (实际的)
2023年10月31日
研究注册日期
首次提交
2021年10月22日
首先提交符合 QC 标准的
2021年10月22日
首次发布 (实际的)
2021年11月3日
研究记录更新
最后更新发布 (实际的)
2024年3月22日
上次提交的符合 QC 标准的更新
2024年3月21日
最后验证
2024年3月1日
更多信息
与本研究相关的术语
其他研究编号
- 2000031171
- 1R21MH123870-01A1 (美国 NIH 拨款/合同)
- 1R01MH113557-01 (美国 NIH 拨款/合同)
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
不
药物和器械信息、研究文件
研究美国 FDA 监管的药品
是的
研究美国 FDA 监管的设备产品
不
在美国制造并从美国出口的产品
不
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.